S&P 500   4,550.86 (-0.36%)
DOW   36,048.86 (-0.21%)
QQQ   385.31 (-0.51%)
AAPL   192.43 (-0.51%)
MSFT   369.21 (-0.89%)
META   317.51 (-0.25%)
GOOGL   130.14 (-0.65%)
AMZN   144.92 (-1.33%)
TSLA   239.95 (+0.52%)
NVDA   456.35 (-2.00%)
NIO   7.81 (+5.11%)
BABA   71.78 (-0.83%)
AMD   116.47 (-1.61%)
T   16.98 (-1.39%)
F   10.72 (+1.13%)
MU   73.11 (-0.79%)
CGC   0.70 (+4.65%)
GE   120.14 (-0.07%)
DIS   91.51 (+0.79%)
AMC   6.81 (-2.99%)
PFE   28.78 (-1.07%)
PYPL   59.37 (+2.50%)
XOM   99.01 (-1.42%)
S&P 500   4,550.86 (-0.36%)
DOW   36,048.86 (-0.21%)
QQQ   385.31 (-0.51%)
AAPL   192.43 (-0.51%)
MSFT   369.21 (-0.89%)
META   317.51 (-0.25%)
GOOGL   130.14 (-0.65%)
AMZN   144.92 (-1.33%)
TSLA   239.95 (+0.52%)
NVDA   456.35 (-2.00%)
NIO   7.81 (+5.11%)
BABA   71.78 (-0.83%)
AMD   116.47 (-1.61%)
T   16.98 (-1.39%)
F   10.72 (+1.13%)
MU   73.11 (-0.79%)
CGC   0.70 (+4.65%)
GE   120.14 (-0.07%)
DIS   91.51 (+0.79%)
AMC   6.81 (-2.99%)
PFE   28.78 (-1.07%)
PYPL   59.37 (+2.50%)
XOM   99.01 (-1.42%)
S&P 500   4,550.86 (-0.36%)
DOW   36,048.86 (-0.21%)
QQQ   385.31 (-0.51%)
AAPL   192.43 (-0.51%)
MSFT   369.21 (-0.89%)
META   317.51 (-0.25%)
GOOGL   130.14 (-0.65%)
AMZN   144.92 (-1.33%)
TSLA   239.95 (+0.52%)
NVDA   456.35 (-2.00%)
NIO   7.81 (+5.11%)
BABA   71.78 (-0.83%)
AMD   116.47 (-1.61%)
T   16.98 (-1.39%)
F   10.72 (+1.13%)
MU   73.11 (-0.79%)
CGC   0.70 (+4.65%)
GE   120.14 (-0.07%)
DIS   91.51 (+0.79%)
AMC   6.81 (-2.99%)
PFE   28.78 (-1.07%)
PYPL   59.37 (+2.50%)
XOM   99.01 (-1.42%)
S&P 500   4,550.86 (-0.36%)
DOW   36,048.86 (-0.21%)
QQQ   385.31 (-0.51%)
AAPL   192.43 (-0.51%)
MSFT   369.21 (-0.89%)
META   317.51 (-0.25%)
GOOGL   130.14 (-0.65%)
AMZN   144.92 (-1.33%)
TSLA   239.95 (+0.52%)
NVDA   456.35 (-2.00%)
NIO   7.81 (+5.11%)
BABA   71.78 (-0.83%)
AMD   116.47 (-1.61%)
T   16.98 (-1.39%)
F   10.72 (+1.13%)
MU   73.11 (-0.79%)
CGC   0.70 (+4.65%)
GE   120.14 (-0.07%)
DIS   91.51 (+0.79%)
AMC   6.81 (-2.99%)
PFE   28.78 (-1.07%)
PYPL   59.37 (+2.50%)
XOM   99.01 (-1.42%)

Lantheus Stock Price, News & Analysis (NASDAQ:LNTH)

$71.99
-0.68 (-0.94%)
(As of 03:27 PM ET)
Compare
Today's Range
$71.86
▼
$73.97
50-Day Range
$61.58
▼
$76.34
52-Week Range
$47.46
▼
$100.85
Volume
549,066 shs
Average Volume
1.00 million shs
Market Capitalization
$4.93 billion
P/E Ratio
50.34
Dividend Yield
N/A
Price Target
$110.71
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Lantheus MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
53.4% Upside
$110.71 Price Target
Short Interest
Bearish
7.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.67
Upright™ Environmental Score
News Sentiment
0.73mentions of Lantheus in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$1.06 M Sold Last Quarter
Proj. Earnings Growth
3.20%
From $5.31 to $5.48 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.86 out of 5 stars

Medical Sector

46th out of 953 stocks

Drug Manufacturers - Specialty & Generic Industry

1st out of 11 stocks

See Top Rated MarketRank™ Stocks Here

LNTH stock logo

About Lantheus Stock (NASDAQ:LNTH)

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent. The company also offers AZEDRA, a radiotherapeutic therapy; Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; PNT2002 for pre-chemotherapy patients; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; and PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer. The company serves hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, distirbutors, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; and FUJIFILM. The company was founded in 1956 and is based in Bedford, Massachusetts.

LNTH Stock Price History

LNTH Stock News Headlines

December 5, 2023 | markets.businessinsider.com
Strong Market Outlook for Lantheus’s Pylarify and Therapeutic Candidate PNT2002 Reinforces Buy Rating
December 5, 2023 | americanbankingnews.com
TD Cowen Initiates Coverage on Lantheus (NASDAQ:LNTH)
December 6, 2023 | Edge On The Street (Ad)
Henry Ford Would NEVER Have Seen This Coming
In 1908, Henry Ford used a metal called vanadium in his Model T cars. Over a century later, automakers still turn to vanadium to make car bodies lighter and stronger. Today, this under-appreciated metal plays the starring role in cutting-edge battery tech set to revolutionize the energy storage market.
December 4, 2023 | markets.businessinsider.com
Buy Rating Affirmed for Lantheus: Strong Market Position and Growth Prospects in Precision Diagnostics
December 1, 2023 | americanbankingnews.com
Lantheus (NASDAQ:LNTH) Coverage Initiated by Analysts at Brookline Capital Management
November 30, 2023 | benzinga.com
Lantheus Holdings Stock (NASDAQ:LNTH) Dividends: History, Yield and Dates
November 30, 2023 | msn.com
Brookline Capital Initiates Coverage of Lantheus Holdings (LNTH) with Buy Recommendation
November 30, 2023 | markets.businessinsider.com
The Latest Analyst Ratings for Lantheus Holdings
December 6, 2023 | DTI Trader (Ad)
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
November 22, 2023 | finance.yahoo.com
Investors Met With Slowing Returns on Capital At Lantheus Holdings (NASDAQ:LNTH)
November 22, 2023 | morningstar.com
Lantheus Holdings Inc LNTH
November 12, 2023 | seekingalpha.com
Lantheus Holdings: Huge Catalysts Ahead And Cheap Valuation
November 6, 2023 | markets.businessinsider.com
Undervalued Lantheus: High-Growth Prospects and Potential Expansion Opportunities Support Buy Rating
November 6, 2023 | markets.businessinsider.com
Strong Q3 2023 Performance and Future Potential Drive Analyst’s Buy Rating for Lantheus
November 5, 2023 | finance.yahoo.com
An Intrinsic Calculation For Lantheus Holdings, Inc. (NASDAQ:LNTH) Suggests It's 22% Undervalued
November 4, 2023 | finance.yahoo.com
Lantheus Holdings, Inc. (NASDAQ:LNTH) Q3 2023 Earnings Call Transcript
November 4, 2023 | benzinga.com
Lantheus Holdings Stock (NASDAQ:LNTH), Analyst Ratings, Price Targets, Predictions
November 3, 2023 | markets.businessinsider.com
Strong Financial Performance and Growth Potential Drive Buy Rating for Lantheus: An Analysis of Undervalued Stock in the MedTech Sector
November 3, 2023 | markets.businessinsider.com
Lantheus’ Strong Financial Performance and Promising Radiopharmaceuticals Drive Analyst’s Buy Rating and $114 Price Target
November 3, 2023 | markets.businessinsider.com
Positive Growth Prospects and Resilient Financial Performance Reinforce Buy Rating for Lantheus Holdings, Inc.
November 2, 2023 | seekingalpha.com
Lantheus Holdings, Inc. 2023 Q3 - Results - Earnings Call Presentation
November 2, 2023 | finance.yahoo.com
Compared to Estimates, Lantheus Holdings (LNTH) Q3 Earnings: A Look at Key Metrics
November 2, 2023 | markets.businessinsider.com
Lantheus Reports Third Quarter 2023 Financial Results
November 2, 2023 | finance.yahoo.com
Lantheus Holdings Inc (LNTH) Reports 33.7% Increase in Q3 2023 Revenue and Doubled Net Income
November 1, 2023 | finance.yahoo.com
Lantheus (LNTH) to Report Q3 Earnings: What's in the Cards?
October 26, 2023 | finance.yahoo.com
Lantheus Holdings (LNTH) Stock Moves -1.02%: What You Should Know
October 19, 2023 | msn.com
Lantheus Holdings (LNTH) Falls More Steeply Than Broader Market: What Investors Need to Know
See More Headlines
Receive LNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LNTH
CUSIP
N/A
CIK
1521036
Web
www.lantheus.com
Phone
(978) 671-8001
Fax
978-671-8860
Employees
698
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$110.71
High Stock Price Target
$127.00
Low Stock Price Target
$100.00
Potential Upside/Downside
+52.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$1.43
Trailing P/E Ratio
50.82
Forward P/E Ratio
13.69
P/E Growth
N/A
Net Income
$28.07 million
Net Margins
8.63%
Pretax Margin
7.99%
Return on Equity
70.13%
Return on Assets
27.19%

Debt

Debt-to-Equity Ratio
0.80
Current Ratio
5.37
Quick Ratio
5.05

Sales & Book Value

Annual Sales
$935.06 million
Price / Sales
5.32
Cash Flow
$4.66 per share
Price / Cash Flow
15.60
Book Value
$6.50 per share
Price / Book
11.18

Miscellaneous

Outstanding Shares
68,490,000
Free Float
67,462,000
Market Cap
$4.98 billion
Optionable
Optionable
Beta
0.66
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report














LNTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Lantheus stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LNTH shares.
View LNTH analyst ratings or view top-rated stocks.

What is Lantheus' stock price target for 2024?

7 equities research analysts have issued twelve-month price objectives for Lantheus' stock. Their LNTH share price targets range from $100.00 to $127.00. On average, they expect the company's stock price to reach $110.71 in the next twelve months. This suggests a possible upside of 53.4% from the stock's current price.
View analysts price targets for LNTH or view top-rated stocks among Wall Street analysts.

How have LNTH shares performed in 2023?

Lantheus' stock was trading at $50.96 at the start of the year. Since then, LNTH stock has increased by 41.6% and is now trading at $72.16.
View the best growth stocks for 2023 here.

When is Lantheus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our LNTH earnings forecast.

How were Lantheus' earnings last quarter?

Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its quarterly earnings data on Thursday, November, 2nd. The medical equipment provider reported $1.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.19 by $0.10. The medical equipment provider earned $319.95 million during the quarter, compared to analyst estimates of $315.01 million. Lantheus had a trailing twelve-month return on equity of 70.13% and a net margin of 8.63%.

What ETFs hold Lantheus' stock?

ETFs with the largest weight of Lantheus (NASDAQ:LNTH) stock in their portfolio include Harbor Health Care ETF (MEDI), Invesco S&P MidCap Momentum ETF (XMMO), SPDR S&P Health Care Equipment ETF (XHE), Harbor Small Cap Explorer ETF (QWST), American Century Mid Cap Growth Impact (MID), Invesco S&P MidCap 400 Pure Growth ETF (RFG), First Trust Active Factor Small Cap ETF (AFSM) and SoFi Next 500 ETF (SFYX).

What guidance has Lantheus issued on next quarter's earnings?

Lantheus issued an update on its FY23 earnings guidance on Thursday, November, 2nd. The company provided EPS guidance of $5.60-$5.70 for the period, compared to the consensus estimate of $5.68. The company issued revenue guidance of $1.245-$1.270 billion, compared to the consensus revenue estimate of $1.26 billion.

What is Mary Anne Heino's approval rating as Lantheus' CEO?

4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lantheus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Exelixis (EXEL), Gerdau (GGB), Pieris Pharmaceuticals (PIRS) and Abeona Therapeutics (ABEO).

When did Lantheus IPO?

(LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

Who are Lantheus' major shareholders?

Lantheus' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (3.13%), American Century Companies Inc. (1.90%), Westfield Capital Management Co. LP (1.89%), Invesco Ltd. (1.54%), Northern Trust Corp (1.44%) and Reinhart Partners LLC. (1.32%). Insiders that own company stock include Andrea Sabens, Brian A Markison, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, Heinz Christoph Maeusli, John J Bolla, Mary Anne Heino, Michael P Duffy, Michael P Duffy, Minnie Baylor-Henry, Paul Blanchfield, Robert J Jr Marshall and Sam R Leno.
View institutional ownership trends.

How do I buy shares of Lantheus?

Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:LNTH) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -